[Weekly paclitaxel therapy for locoregional lymph node recurrence of estrogen-receptor-negative breast cancer].
We treated 7 patients with locoregional lymph node recurrence of estrogen-receptor-negative breast cancer with weekly paclitaxel (TXL) therapy. TXL was administered by 30-minute infusion at a dose of 80 mg/m2 after short premedication every week on an outpatient basis. Administration was continued for 3 weeks with a 1 week rest. Five patients had received prior anthracycline therapy. No patients had received prior therapy for recurrence. The median number of cycles was 4.9 cycles (range, 3-6 cycles). The overall response rate was 84% among 5 complete responders and 1 partial responder. Four of 5 complete responders relapsed after the completion of weekly TXL therapy. Grade 2 leukopenia occurred in 3 patients, and grade 1 peripheral neuropathy occurred in 1 patient. No patients had a serious side effect. Weekly TXL therapy is effective and well tolerated in patients with locoregional lymph node recurrence of estrogen-receptor-negative breast cancer, but the problem of recurrence to other sites after treatment remains to be solved.
Nishimura
Hideki
H
Dept. of Surgery, Nagano Municipal Hospital.
Hamanaka
Kazutoshi
K
Sakai
Hiroshi
H
Ohno
Yasunari
Y
Miyagawa
Yusuke
Y
Seki
Hitoshi
H
Munakata
Yasuhiro
Y
D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D011960:Receptors, Estrogen / Q000032:analysis*
D000972:Antineoplastic Agents, Phytogenic; D011960:Receptors, Estrogen; D017239:Paclitaxel